Hitt J Sharma, Sameer Parekh, Pramod Pujari, Sunil Shewale, Shivani Desai, Anand Kawade, Mandyam Ravi, Jitendra Oswal, Saji James, N Mahantashetti, Renuka Munshi, Apurba Ghosh, Venkateshwar Rao, Sundaram Balsubramaniam, P Varughese, A Somshekhar, Amy Sarah Ginsburg, Harish Rao, Manish Gautam, Sunil Gairola, Umesh Shaligram
BACKGROUND: This study assessed safety and immunogenicity of Serum Institute of India Pvt Ltd (SIIPL)'s tetanus toxoid (TT), diphtheria toxoid (DT), and acellular pertussis booster vaccine (Tdap). RESEARCH DESIGN AND METHODS: In this Phase II/III, multicenter, randomized, active-controlled, open-label study, 1500 healthy individuals, aged 4 - 65 years, were randomized to receive a single dose of SIIPL Tdap or comparator Tdap vaccine (Boostrix®; GlaxoSmithKlines, India)...
March 8, 2023: Expert Review of Vaccines